Please try another search
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/II clinical trial for neuroendocrine tumors indications; ELC-201 for the treatment of various injectable solid tumors; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy for the treatment of solid tumors. Elicera Therapeutics AB (publ) has collaboration with the Josep Carreras Leukemia Research Institute to provide iTANK platform. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Agneta Edberg | 66 | 2020 | Independent Chairman |
Jan Zetterberg | 71 | 2020 | Independent Director |
Christina Herder | 61 | 2020 | Independent Director |
Margareth Jorvid | 61 | 2020 | Independent Director |
Magnus Essand | 59 | 2014 | Chief Science Officer, Co-Founder & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review